Axsome Therapeutics/$AXSM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Axsome Therapeutics

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Ticker

$AXSM
Primary listing

Industry

Pharmaceuticals

Employees

712

ISIN

US05464T1043

AXSM Metrics

BasicAdvanced
$5.1B
-
-$5.77
0.45
-

What the Analysts think about AXSM

Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.

Bulls say / Bears say

Axsome Therapeutics' lead product, AUVELITY, has demonstrated strong commercial performance in treating major depressive disorder, with third-quarter 2024 revenues reaching $104.8 million, surpassing analyst projections. (Investing.com)
The FDA approved Axsome's migraine treatment, Symbravo, in January 2025, expanding the company's product portfolio and potential revenue streams. (Reuters)
Analysts have raised their price targets for Axsome, with Needham & Company LLC increasing it to $153.00, reflecting confidence in the company's growth prospects. (MarketBeat)
Axsome's reliance on the success of key products, particularly AXS-05, poses a risk; any setbacks in clinical trials or regulatory approvals could significantly impact the company's growth prospects. (Investing.com)
The company's high debt-to-equity ratio of 132% raises concerns about financial stability and the ability to manage obligations effectively. (Yahoo Finance)
Increased competition in the CNS therapeutics market, including potential new entrants and existing competitors enhancing their offerings, may challenge Axsome's ability to maintain market share. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

AXSM Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AXSM Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AXSM

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs